TY - JOUR. T1 - American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III. T2 - Low-dose-rate and pulsed-dose-rate brachytherapy. AU - Lee, Larissa J.. AU - Das, Indra J.. AU - Higgins, Susan A.. AU - Jhingran, Anuja. AU - Small, William. AU - Thomadsen, Bruce. AU - Viswanathan, Akila N.. AU - Wolfson, Aaron. AU - Eifel, Patricia. PY - 2012/1/1. Y1 - 2012/1/1. N2 - Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive ...
TOLEDO, OH - 5 Apr, 2017 - Bionix Radiation Therapy will be exhibiting at the 2017 American Brachytherapy Society Annual meeting in Boston, Massachusetts, from April 20-22, 2017.. Bionix will be featuring cutting edge precision balloon technology for esophageal, anal and rectal cancers. Bionix is excited to announce a new brachytherapy solution at the ABS Annual meeting, be sure to visit booth #310 to witness the unveiling of this new solution.. The event takes place at the Seaport Hotel in Boston, Massachusetts. Bionix will be showcasing their solutions for anal and rectal cancers, the AR-1TM, or anorectal applicator, a disposable brachytherapy applicator designed specifically for the treatment of anal and rectal cancers. Along with the E-AppTM, or esophageal applicator, a disposable brachytherapy applicator designed specifically for the treatment of upper GI cancers.. To learn more about the 2017 American Brachytherapy Society Annual Meeting, visit their Website at: ...
Thiagarajan, A., Lin, K., Lu, J.J., Tan, L.K.S., Loh, T.K.S., Goh, B.C., Lin, K., Tiong, C.E. (2006). Sequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: An evaluation of long-term outcome. Laryngoscope 116 (6) : 938-943. [email protected] Repository. https://doi.org/10.1097/01.MLG.0000215173.14473. ...
Capital Regional Cancer Center also offers High-Dose Rate Brachytherapy (HDR) - an internal radiation therapy method that delivers a highly localized therapeutic dose of radiation directly to the tumor location. The radioactive source is applied using temporarily placed applicators. HDR involves a shortened treatment duration and is almost performed as an outpatient. As the therapy is extremely focused, the dose to surrounding organs and tissues is minimized, reducing potential side effects of treatment.. ...
Permanent prostate brachytherapy involves placing many radioactive seeds within the prostate to treat prostate cancer. During the procedure, an ultrasound probe is placed in the rectum to help guide the placement of seeds. The seeds emit radiation that dissipates over a few months.. ...
BEBIG - brachytherapy prostate cancer, brachytherapy for prostate cancer, microsources for brachytherapy treatment of prostate cancer
Lu, J.J., Shakespeare, T., Back, M., Mukherjee, R., Wynne, C.J., Goh, B.C., Tan, K.S.L., Tiong, C.E. (2004). Adjuvant High-Dose Rate Brachytherapy after Chemoradiation for Treatment of Early T-Stage Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials 27 (2) : 132-135. [email protected] Repository. https://doi.org/10.1097/01.coc.0000046592.90778. ...
It is with great enthusiasm and anticipation that we invite you to attend the 2017 American Brachytherapy Society (ABS) Annual Meeting. Our meeting theme is "the Value of Brachytherapy in Multidisciplinary Cancer Care" and the meeting will be held at the Boston World Trade Center in the historic city of Boston, from April 20 - 22. Dan Petereit and Ann Kopp our Scientific Program Chairs for the meeting, and together with the co-chairs is putting together a very enriching and stimulating program. A wide variety of national and international speakers have been invited to present their data and to debate controversial issues. We will again offer the Judith Stitt Best Abstract Awards that will be highlighted in a plenary session. The Resident Travel Awards will continue to encourage resident involvement in the society and we will again offer a Residents Luncheon at our meeting. The Seaport Hotel & World Trade Center is Located in the bustling Seaport District, one of Bostons most popular ...
Experiences of high dose rate brachytherapy: Hello, I was diagnosed 2 weeks ago. I have stage T2 with Gleason of 3+4, and psa of 10. Although it seems to be contained it appears to be close to the nerves surrounding the prostate which makes nerve sparing RP unlikely to succeed. I have been...
TY - JOUR. T1 - High-dose-rate brachytherapy using molds for lip and oral cavity tumors. AU - Unetsubo, Teruhisa. AU - Matsuzaki, Hidenobu. AU - Takemoto, Mitsuhiro. AU - Katsui, Kuniaki. AU - Hara, Marina. AU - Katayama, Norihisa. AU - Waki, Takahiro. AU - Kanazawa, Susumu. AU - Asaumi, Jun-Ichi. PY - 2015/4/8. Y1 - 2015/4/8. N2 - Background: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this retrospective study, we evaluated the outcome of this therapy and investigated its feasibility for lip and oral cavity tumors. Methods: Between May 2002 and December 2010, 17 patients (median age, 80.0years) with histologically confirmed squamous cell carcinoma of the lip or oral cavity were treated by means of HDR brachytherapy using the mold technique after external beam radiotherapy (EBRT). Tumor sites included the buccal mucosa in eight cases, the ...
A noteworthy study recently published in JAMA® (The Journal of the American Medical Association) by a multi-institutional group of prostate cancer experts, concluded that men with high risk prostate cancer treated with external beam radiation therapy (EBRT), brachytherapy seed implant, and hormone deprivation therapy, were associated with significantly better prostate cancer-specific mortality rates (deaths caused by prostate cancer) compared to radical prostatectomy or EBRT with hormone deprivation therapy.2. Additionally, researchers from the British Columbia Cancer Agency, published a landmark, Level 1 evidence trial, that concluded men with Intermediate & High-Risk prostate cancer randomized to low-dose brachytherapy boost, EBRT, and hormone deprivation (versus men randomized to EBRT boost, EBRT and hormone deprivation therapy) were twice as likely to be free of biochemical failure (detectable and rising Prostate Specific Antigen (PSA)) at a median follow-up of 6.5 years.3. Peter Orio, DO, ...
1 Sung et al. Safety and efficacy of radioactive seed localization with I-125 prior to lumpectomy and/or excisional biopsy. European Journal of Radiology. 2013; 82. 1453-1457. 2 Chiu et al. Radioactive seed localization of non-palpable breast lesions in an academic comprehensive cancer program community hospital setting. The American Surgeon. 2014; 80: 675-679. 3 Diego et al. Localizing high risk lesions for excisional breast biopsy: a comparison between radioactive seed localization and wire localization. Annals of Surgical Oncology. 2014; 21: 3268-3272. 4 Barentsz et al. Radioactive seed localization for non-palpable breast cancer. British Journal of Surgery. 2013; 100: 582-588. 5 Murphy et al. Radioactive seed localization compared to wire localization in breast-conserving surgery: Initial 6-Month Experience. Annals of Surgical Oncology. 2013; 20: 4121-4127. 6 McGhan et al. Radioactive seed localization for non-palpable breast lesions: Review of 1,000 consecutive procedures at a single ...
ALSIO VIEJO, Calif. - Cianna Medical, maker of the SAVI® breast brachytherapy applicator, recently announced the launch of BEST Forum™, a new educational resource for physicians to obtain the latest findings and research in breast brachytherapy and gain insights into best practices and available technology.. Both online and in person, BEST Forum (www.theBESTForum.com) brings together world-renowned thought leaders in the field of breast cancer care to discuss their extensive experiences and research in brachytherapy, treatment and clinical outcomes.. Breast brachytherapy is a form of accelerated partial breast irradiation (APBI), a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery.. At the BEST Forum website, which launched in early May, physicians can view presentations from brachytherapy experts, as well as download white papers, presentation slides and supporting clinical data, and register for future presentations.. "Were excited to ...
There has been much controversy over the past several years regarding the best treatment option for prostate cancer. To date, there is no clear-cut data to prove the advantage of surgery over other treatment options. Recently, there has been a new enthusiasm for IMRT (Intensity Modulated Radiation Therapy) and proton beam radiation therapy for the treatment of prostate cancer. Again, there is no data to support that either therapy is superior to brachytherapy for the treatment of prostate cancer. However, there is data suggesting that brachytherapy is superior to IMRT. Data from the latest Meeting of the American Brachytherapy Society, presented by Michael Zelefsky, M.D. from Sloan-Kettering Cancer Center, NY (June 2009), compared 2292 patients that were treated with IMRT or brachytherapy. Results found that the 7-year PSA relapse-free survival (PRFS) for low-risk patients was 92.4% for patients treated with brachytherapy and 91.6% for patients treated with IMRT. However, the 7-year PRFS for ...
Even though the women in the study were treated with brachytherapy before the ASTRO guidelines were developed, the results suggest that many women unsuitable for brachytherapy are getting brachytherapy. This possibility is more of a concern because brachytherapy use has continued to increase since 2007 when the last of the patients in this study were treated.. Findings from another large study suggest that brachytherapy may not be as effective as whole-breast radiation therapy at reducing recurrence risk. Women in that study who got brachytherapy after lumpectomy for early-stage breast cancer were nearly twice as likely to later have a mastectomy because of cancer recurrence compared to women who got traditional whole-breast radiation therapy. That study also found that treatment complications -- such as rib fracture, breakdown of fat in the breast (fat necrosis), breast pain, and inflammation in the lungs -- were more likely among women treated with brachytherapy. Some of these higher ...
The article outlines the approach to applying the mechatronic technologies and robotic systems in carrying out the brachytherapy operations. To calculate the elastic state of the flexible needles of different geometry in the prostate model, a mathematical model of the flexible needle deformation has been applied which took into account the medium reaction and was based on the theory of flexible and elastic rods. The numeric calculations for different types of needles have been introduced for the first time. Also for the first time the advantages of applying flexible needles for brachytherapy procedure have been mathematically justified.
Treatment of prostate cancer with interstitial brachytherapy (radioactive seeds implantation) (costs for program #49753) ✔ St. Antonius Hospital ✔ Department of Urology and Pediatric Urology ✔ BookingHealth.com
Principal Investigator:TOITA Takafumi, Project Period (FY):2004 - 2005, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Radiation science
... has been successfully modified by scientists at Isotopen Technologie München AG (ITM), solving problems of radiation exposure to Rhenium-188. The researchers are now producing Rhenium-188 with previously unknown high specific activity in a new type of generator, Isotopen Technologie reports. |br /|, Endovascular brachytherapy has been successfully modified by scientists at Isotopen Technologie München AG (ITM), solving problems of radiation exposure to Rhenium-188. The researchers are now producing Rhenium-188 with previously unknown high specific activity in a new type of generator, Isotopen Technologie reports. |br /|
The Head and Neck Working Group of the GEC-ESTRO (Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology) published in 2009 the consensus recommendations for low-dose rate, pulsed-dose rate and high-dose rate brachytherapy in head & neck cancers. The use of brachytherapy in combination with external beam radiotherapy and/or surgery was also covered as well as the use of brachytherapy in previously irradiated patients. Given the developments in the field, these recommendations needed to be updated to reflect up-to-date knowledge.. The present update does not repeat basic knowledge which was published in the first recommendation but covers in a general part developments in (1) dose and fractionation, (2) aspects of treatment selection for brachytherapy alone versus combined BT+EBRT and (3) quality assurance issues.. Detailed expert committee opinion intends to help the clinical practice in lip-, oral cavity-, oropharynx-, nasopharynx-, and superficial cancers. ...
... Published by QYResearch at researchbeam.com . Global Brachytherapy Afterloaders, Brachytherapy Seeds Industry 2016 Deep Market Research Report is a research report by Key Manufacturers, Applications, Developments and Trends with covering regions China, US, Europe & Japan
Learn about brachytherapy seeds, is a basic part of brachytherapy treatments for cancer. Radiation can be delivered inside the body using a brachytherapy seed.
The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients. External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped, because these tumors are radiographically invisible ...
TY - JOUR. T1 - Trans-urethral ultrasound imaging of the prostate for applications in prostate brachytherapy. T2 - Medical Imaging 2001: Visualization, Display, and Image-Guided Procedures. AU - Holmes, D.. AU - Davis, B.. AU - Bruce, C.. AU - Wilson, T.. AU - Robb, R.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - 3D Trans-Urethral Ultrasound (TUUS) imaging is a new imaging technique for the diagnosis and treatment of prostate disease. Our current research focuses on the potential of TUUS in therapy guidance during transperineal interstitial permanent prostate brachytherapy (TIPPB). TUUS may complement or potentially replace x-ray fluoroscopy and TRUS in providing data for determining the prostate boundary and radiation source locations. Prostate boundary detection and source localization using TUUS were tested on an ultrasound-equivalent prostate phantom and in a patient during TIPPB. Data collection was conducted with a 10 French, 10 MHz ultrasound catheter controlled by an Acuson Sequoia™ ...
SAM-CME credits available here High dose rate (HDR) brachytherapy has been an option for managing localized prostate cancer since the early 1990s. Several fe...
ISO 21439:2009 specifies methods for the determination of absorbed-dose distributions in water or tissue that are required prior to initiating procedures for the application of beta radiation in ophthalmic tumour and intravascular brachytherapy]. Recommendations are given for beta-radiation source calibration, dosemetry measurements, dose calculation, dosemetric quality assurance, as well as for beta-radiation brachytherapy treatment planning. Guidance is also given for estimating the uncertainty of the absorbed dose to water. ISO 21439:2009 is applicable to "sealed" radioactive sources, such as plane and concave surface sources, source trains of single seeds, line sources, shell and volume sources, for which only the beta radiation emitted is of therapeutic relevance.. The standardization of procedures in clinical dosemetry described in ISO 21439:2009 serves as a basis for the reliable application of beta-radiation brachytherapy. The specific dosemetric methods described in ISO 21439:2009 apply ...
Purpose: Treatment of choroidal melanoma (CMM) with either iodine-125 (I125) plaque brachytherapy or enucleation yields similar survival outcomes. As such, we have used brachytherapy as primary treatment for large CMMs for more than a decade. Herein, we evaluate our cohort of patients with large CMM initially treated with plaque brachytherapy to determine rate of and factors associated with secondary enucleation.. Methods: A retrospective chart review of patients with large CMMs diagnosed and treated at our institution from January 1, 1988 to February 1 2013. Main outcome measures were need for secondary enucleation, local tumor recurrence, all cause mortality, development of metastases, initial apical tumor height and maximal basal diameter.. Results: 245 patients with large CMM were treated primarily with plaque brachytherapy. Local control was achieved in 230 patients (93.8%). Of the 15 patients (6.2%) with local recurrence, 8 underwent secondary enucleation and 7 deferred further treatment. ...
Within the recent resurgence of brachytherapy as treatment for prostate cancer, many new devices have been conceived in the preparation of surgical brachytherapy equipment. Specifically, this work encompasses the automated preparation of preloaded surgical brachytherapy applicators or "needles" through the loading of radioactive seed elements and benign spacer elements. While traditionally a manual operation, current device methodology in this application revolves around semi-automatic mechanical interaction within the element loading procedure. Mechanical interaction can subject elements to damage, specifically seed elements due to thin metallic construct. Damage to elements within a loading system can result in failure of the performed brachytherapy treatment causing potential harm to the patient. Hesitancy in acceptance of these mechanical separation element loading devices can be attributed to the failure nature of these devices. This work seeks to solve the current issue of element damage ...
Purpose The treatment planning (TP) in high-dose-rate (HDR) endobronchial brachytherapy (EB) can be based on various forms of imaging. In the case of lung cancer, one-dimensional or two-dimensional imaging is standard. The dose coverage of the target (planning target volume - PTV) and organs...
The UWADCL is capable of calibrating the following low energy brachytherapy sources, or applicable well chambers utilizing them. All sources are calibrated in units of air kerma strength (U). For I-125, Pd-103, and Ir-192, each source model is a separate calibration point. The Cs-137 calibration point will cover most tube-type sources in the medical community.. For dosimetry information regarding specific seed models, please click here to go to the AAPM/RPC Joint Registry of Low-energy Brachytherapy Seeds meeting the AAPM dosimetric prerequisites.. ...
Doctors can use brachytherapy alone or in addition to external-beam radiation therapy to provide a "boost" of radiation to a tumor while sparing surrounding normal tissue. Brachytherapy may be able to deliver higher doses of radiation to some cancers than external-beam radiation therapy while causing less damage to normal tissue.. Several brachytherapy techniques are used in cancer treatment, based on locations of cancer, dose and period of treatment. Interstitial brachytherapy uses a radiation source placed within tumor tissue, such as within a prostate tumor. Intracavitary brachytherapy uses a source placed within a surgical cavity or a body cavity, such as the chest cavity, near a tumor. Episcleral brachytherapy, which is used to treat melanoma inside the eye, uses a source that is attached to the eye.. In interstitial brachytherapy, radioactive isotopes are sealed in tiny pellets, the size of a grain of rice. These seeds are placed in the body using delivery devices, such as needles, ...
A growing instance of cancer across the globe is a primary factor boosting revenue growth of the global brachytherapy devices market. Market Research Reports Search Engine (MRRSE) has studied the global brachytherapy devices market in a new report titled Brachytherapy Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2022. The report focuses on the benefits of brachytherapy as a more effective therapy for the treatment of cancer that employs radiation in doses that are concentrated and localized to the cancer cells. Brachytherapy devices are popular as they facilitate efficient treatment in a relatively shorter time period with low side effects. This is a major growth driver for the global brachytherapy devices market. The report highlights the different drivers and factors likely to impact market growth over the forecast period.. Request for Sample Report: https://www.mrrse.com/sample/3509. The brachytherapy devices market is estimated to reach a ...
The options available for patients with recurrent prostate cancer are limited. Men who have failed external-beam irradiation as the primary treatment are rarely considered for potentially curative salvage therapy. Traditionally, only palliative treatments have been offered with hormonal intervention or simple observation. A significant percentage of these patients have only locally recurrent cancer and are thus candidates for curative salvage therapy. Permanent brachytherapy with iodine-125 or palladium-103 has been used in an attempt to eradicate the remaining prostate cancer and prevent the need for additional intervention. It is critical in this population to identify patients most likely to have distant metastases or who are unlikely to suffer death or morbidity from their recurrence, in order to avoid potential treatment morbidity in those unlikely to benefit from any intervention. Following salvage brachytherapy, up to 98% of these cancers may be locally controlled, and 5-year freedom from second
The dosimetry of sources used in interstitial brachytherapy has been the subject of considerable research in recent years. A number of articles have appeared (Appendix C) introducing revised calibration standards, source strength specification quantities, and dose calculation formalisms. Some of these articles advocate revision of basic dosimetry data, including dose rate constants, radial dose functions, and anisotropy functions for 192Ir, 125I, and 103Pd sources. In particular, the Interstitial Collaborative Working Group (ICWG), which was sponsored by the National Cancer Institute, has completed its final report. With all these reports appearing in the literature, the medical physics community is faced with a confusing situation regarding the selection of dosimetry data. Therefore, the Radiation Therapy Committee of the American Association of Physicists in Medicine (AAPM) in 1988 formed Task Group No. 43 to review the recent publications on the dosimetry of interstitial brachytherapy sources ...
Varian Medical Systems will be exhibiting its complete line of hardware, software, and applicators for HDR and LDR brachytherapy, including the VariSource iX, GammaMedplus iX and the GammaMedplus 3/24 iX HDR afterloaders, the BrachyVision treatment planning system plus the Vitesse module for using transrectal ultrasound (TRUS) images as the basis for a prostate cancer treatment plan. For LDR treatments, the VariSeed treatment planning system is a leading system for this highly specialized form of brachytherapy.. ...
125I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy:a comparison with best supportive care Jingjing Song* Xiaoxi Fan* Zhongwei Zhao* Minjiang Chen* Weiqian Chen, Fazong Wu, Dengke Zhang, Li Chen, Jianfei Tu, Jiansong Ji Department of Interventional Radiology, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, Peoples Republic of China *These authors have contributed equally to this work Objectives: The objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) after one cycle of first-line chemotherapy.Patients and methods: Sixteen patients with locally advanced NSCLC were treated with CT-guided 125I brachytherapy after one cycle of first-line chemotherapy (group A). Sixteen
Brachytherapy (the term is derived from the Greek word brachys, which means brief or short) refers to cancer treatment with ionizing radiation delivered via radioactive material placed a short distance from, or within, the tumor. In prostate cancer, brachytherapy involves the ultrasound- and template-guided insertion of radioactive seeds into...
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether external-beam radiation therapy is more effective with or without indinavir and ritonavir in treating patients with brain metastases.. PURPOSE: This randomized phase II trial is studying external-beam radiation therapy alone to see how well it works compared to external-beam radiation therapy given together with indinavir and ritonavir in treating patients with brain metastases. ...
ALISO VIEJO, Calif. - BioLucent, Inc. today announced the launch of its SAVI™ applicator. The SAVI device offers a multi-catheter, single-entry approach to breast brachytherapy as part of breast-conserving cancer treatment.. The product introduction occurs at the annual meeting of the American Society for Therapeutic Radiation and Oncology (ASTRO), November 5-9 in Philadelphia. BioLucent will exhibit the new device at the companys Booth No. 1439.. The SAVI applicator is for use in accelerated partial breast irradiation (APBI) after lumpectomy. The applicator is a hybrid of two earlier APBI approaches, combining the tissue-sparing dosimetry of interstitial brachytherapy with the single-entry ease of intracavitary ("balloon") brachytherapy.. The SAVI applicators ability to deliver a precisely targeted dose of radiation is designed to give more flexibility in treatment planning to the radiation oncologist and physicist.. APBI was developed as an alternative to whole-breast irradiation. Both ...
A study by researchers at Brigham and Womens Hospital found that brachytherapy treatment was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the United States.
The oncology centre at Netcare Pinehaven Hospital in Krugersdorp has considerably bolstered its cancer treatment options, with the introduction of high dose rate (HDR) brachytherapy, an internally delivered form of radiation therapy for the treatment of various kinds of cancers.. "HDR brachytherapy involves the application of a radioactive source in close proximity to malignant tumours in order to destroy them or reduce their size. Used to treat a range of cancers including cervical, uterus, endometrial, and oesophageal, the introduction of this technology at Netcare Pinehaven Hospital provides oncologists with an important tool in the fight against the disease," says Dr Cindy Aitton, head of Netcares Cancer Care division.. Dr Paul Paradza, one of the oncologists at the hospitals oncology centre, says HDR brachytherapy is highly effective, and can be used as a stand-alone treatment in suitable cases, or in conjunction with other cancer treatments such as chemotherapy, surgery and external beam ...
Apparatus, systems, and methods are provided for delivering brachytherapy into a target tissue region, e.g., a breast. In some embodiments, a flexible brachytherapy device is implanted that includes a therapy delivery portion having one or more radioactive sources securely retained thereto, and a tail portion extending from the therapy delivery portion. The brachytherapy device may be implanted in a helical configuration within the target tissue region. To assist in placement and removal of the brachytherapy device, a tubular sheath may be implanted by attaching (e.g., sliding over) a helically coiled needle that is advanced into the body by screw-like rotation. Once implanted, the sheath and the brachytherapy device may extend outside the body, where they may be folded and secured flat against the skin. The device and sheath may be removed at therapy completion.
For patients with advanced or recurrent gynecologic malignancies, interstitial brachytherapy (ISBT) has been shown to improve local control, while maintaining an acceptable toxicity profile [1]. Patients with complex and bulky disease are often indicated for the brachytherapy component to be delivered using a perineal template to guide the ISBT implant. Though treatment regimens vary, the application of the prescription dose is commonly delivered over three to six fractions from a single perineal implant that is sutured to the patient [1,2,3]. These fractions are delivered a minimum of six hours apart, with the total treatment time spanning multiple, consecutive days. To aid in the safe adoption of complex high-dose-rate (HDR) brachytherapy gynecologic treatments, consensus-based commissioning guidelines provide a standardized approach to minimize treatment errors [4]; however, the availability of institutional resources create differences in practical clinical implementation, which often ...
This study is the first to show that platelet activation is increased by the brachytherapy currently applied in clinical practice. A notable increase was found after brachytherapy compared with PCI without irradiation. We have previously identified increased platelet activation after conventional PCI as an independent risk factor for acute ischaemic events.20 The data on radiation delivery devices submitted for US Food and Drug Administration (FDA) approval showed that patients treated with radiation benefit from a reduction in recurrent stenosis but also have the disadvantage of an increased rate of thrombotic events.192324 Thrombotic occlusions are associated with increased mortality after PCI21 and an increased risk of myocardial infarctions after VBT.1419232526 The increase in platelet activation after brachytherapy is not suppressed by concomitant treatment with aspirin and clopidogrel. Both drugs were given to all 23 patients three to four weeks before elective brachytherapy. In the group ...
Oakland CA (PRWEB) September 17 2013 Dennis R. Hill MD has confirmed today that he will be speaking to the American Cancer Society Man-to-Man support group on High Dose Rate Brachytherapy Tuesday September 24 from 6:30 to 8:00pm at the Summit Campus of Alta Bat,Dennis,R.,Hill,,MD,to,Speak,at,the,American,Cancer,Society,Man-to-Man,Support,Group,to,Discuss,HDR,Brachytherapy,for,Prostate,Cancer,Treatment,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Endobronchial brachytherapy in the treatment of malignant lung tumours.: A prospective study was made to assess the short-term clinical and endoscopic response
All information about the latest scientific publications of the Clínica Universidad de Navarra. High-dose-rate brachytherapy in lower eyelid cancer
Monotherapy with high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy are both recommended modalities for prostate cancer. The choice between HDR and LDR is dependent on patient, physician, and hospital preferences.
Brachytherapy in the treatment of cervical cancer: a review Robyn Banerjee,1 Mitchell Kamrava21Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada; 2Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USAAbstract: Dramatic advances have been made in brachytherapy for cervical cancer. Radiation treatment planning has evolved from two-dimensional to three-dimensional, incorporating magnetic resonance imaging and/or computed tomography into the treatment paradigm. This allows for better delineation and coverage of the tumor, as well as improved avoidance of surrounding organs. Consequently, advanced brachytherapy can achieve very high rates of local control with a reduction in morbidity, compared with historic approaches. This review provides an overview of state-of-the-art gynecologic brachytherapy, with a focus on recent advances and their implications for women with cervical cancer.Keywords: cervical cancer, brachytherapy, image-guided
Radiation therapy might hurt men by inadvertently damaging their rectum. Men considering radiation therapy would be wise to ask their radiation oncologist about SpaceOar, a hydrogel product. SpaceOAR stands for Spacing Organs at Risk. Think of SpaceOar as a rectal spacer. Hydrogel is a water-like substance thats injected between the rectum and prostate in order to reduce the radiation dose to the rectum. Published studies have investigated its use with various kinds of radiation- IMRT, 3D-CRT, SBRT, protons, low dose rate brachytherapy, high dose rate brachytherapy, salvage radiation after primary prostatectomy, and salvage brachytherapy after primary radiation. Those studies say hydrogel is usually safe and adds about 12mm of space between the rectum and prostate. Very few men will feel the hydrogel - it is fully absorbed by your body within a year and then pissed out.. SpaceOar may have a very useful role in men with bowel inflammation, a history of rectal issues (hemorrhoids, for example), ...